For US residents only.

KISQALI Is Now FDA Approved

An option for postmenopausal women with HR+ (ER+ and/or PR+), HER2- metastatic breast cancer, in combination with hormone therapy

Important Safety Information:

What is the most important information I should know about KISQALI?

KISQALI may cause serious side effects, including:

Heart rhythm problems (QT prolongation). KISQALI can cause a heart problem kno...

See More
Approved Use:

KISQALI® (ribociclib) is a prescription medicine used in combination with a certain type of medicine as the first hormonal-based therapy to treat women who have gone through menopause with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negati...

See More
KISQALI MEDICATION INFORMATION

Treatment Information

Explore details about treatment with KISQALI, including side effect information and dosing instructions.

LEARN MORE
SUPPORT MADE SIMPLE

Patient Support

The KISQALI Care Patient Support Program offers customized services and information about financial assistance options.

LEARN MORE